A randomised, open-label, multicentre, efficacy and safety study examining the effects on viral kinetics of all-trans retinoic acid (tretinoin) (Vesanoid) in combination with pegylated interferon alpha-2a (Pegasys) and ribavirin (Copegus) therapy in patients with genotype 1-chronic hepatitis C and non-response to a previous course of peg-interferon alpha/ribavirin combination (ATRACTION)

Trial Profile

A randomised, open-label, multicentre, efficacy and safety study examining the effects on viral kinetics of all-trans retinoic acid (tretinoin) (Vesanoid) in combination with pegylated interferon alpha-2a (Pegasys) and ribavirin (Copegus) therapy in patients with genotype 1-chronic hepatitis C and non-response to a previous course of peg-interferon alpha/ribavirin combination (ATRACTION)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2013

At a glance

  • Drugs Tretinoin (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Acronyms ATRACTION; MZ-ATRACTION
  • Most Recent Events

    • 31 Oct 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 13 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top